Clinical Trials Browser

Phase 1/2 × Hodgkin Disease × pembrolizumab × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02362035 2025-12-11

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03331341 2025-08-05

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Phase 1/2 Completed

50 enrolled 10 charts

Lymphoid

Hodgkin Disease

NCT02875067 2020-08-14

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Phase 1/2 Terminated

6 enrolled 5 charts

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT02408042 2017-06-27

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Phase 1/2 Withdrawn

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

Clinical Trials

MK-4280-003

KEYNOTE145

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)